Form 4: Hims & Hers Health CFO Oluyemi Okupe Executes Stock Options and Sells Shares Under 10b5-1 Plan

Hims & Hers Health CFO Oluyemi Okupe exercised stock options and sold shares of Class A Common Stock on April 15, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On April 15, 2025, Oluyemi Okupe, the Chief Financial Officer of Hims & Hers Health, Inc., executed stock options to acquire 1,400 shares at $11.53 and 5,037 shares at $5.01.
• Okupe then sold 11,581 shares of Class A Common Stock at an average price of $28.502, with prices ranging from $28.33 to $28.745.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on May 31, 2024.
• Following these transactions, Okupe directly owns 118,960 shares of Class A Common Stock and holds options for 463,628 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports stock transactions by an executive under a pre-arranged plan. There's no inherent positive or negative signal, but the market's reaction will depend on its interpretation of the executive's actions.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. The use of a 10b5-1 trading plan is a standard practice to avoid insider trading concerns.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a significant component.
• The vesting schedules and exercise prices are typical for stock option grants.
• The use of 10b5-1 trading plans is a common practice among executives to manage their stock holdings in compliance with insider trading regulations.
• Comparing Okupe's transactions to those of executives at similar-stage telehealth companies (e.g., Teladoc, Amwell) could provide a benchmark for assessing the magnitude and frequency of these transactions.

Stakeholder Impact

• The transactions could have a minor impact on shareholders depending on how the market interprets the executive's stock sales.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates

Keywords

Hims & Hers Health, Oluyemi Okupe, CFO, stock options, Class A Common Stock, Form 4, 10b5-1 trading plan, insider trading